Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis

Citations Over TimeTop 10% of 2015 papers

Abstract

Growing evidence suggests serum C-reactive protein (CRP) can serve as a prognostic marker in urological cancers. However, some studies yield contradictory results. Our objective was to determine the relationship between baseline serum CRP and survival outcome in urological cancers. We searched PubMed and EMBASE databases until October 2014 without language restrictions. 44 independent studies investigating the association between baseline serum CRP and cancer-specific survival (CSS) or overall survival (OS) were selected. High CRP yielded a worse survival in renal cell carcinoma, prostate cancer, bladder cancer, and upper urinary tract urothelial carcinoma. Combined results of meta-analyses indicated that CRP was a prognostic factor in urological cancers (CSS: p < 0.01; OS: p < 0.01). Subgroup analyses confirmed the significant association between CRP and prognosis, regardless of race and cutoff value of CRP. Specifically, prognostic impact of CRP was also noted in patients with localized RCC treated with nephrectomy (CSS: p < 0.01) and metastatic RCC treated with molecular-targeted therapy (OS: p < 0.01). In conclusion, serum CRP is an independent prognostic factor in urological cancers and risk stratification by serum CRP level could be helpful for prognostic assessment.

Related Papers

• → Partial nephrectomy versus radical nephrectomy for non‐metastatic pathological T3a renal cell carcinoma: A multi‐institutional comparative analysis(2013)34 cited
• Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma.(1999)
• → Partial Nephrectomy in the Treatment of Localized Renal Cell Carcinoma — Experience of Taichung Veterans General Hospital(2007)5 cited
• → Surgery in renal cell carcinoma—when, whom and how?(2019)1 cited
• → The Role of Nephrectomy in Metastatic Renal Cell Carcinoma(1994)